Parkinson's disease -the debate on the clinical phenomenology, aetiology, pathology and pathogenesis
Research output: Contribution to journal › Review article › peer-review
Standard Standard
In: Journal of Parkinson's disease, Vol. 3, No. 1, 2013, p. 1-11.
Research output: Contribution to journal › Review article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Parkinson's disease -the debate on the clinical phenomenology, aetiology, pathology and pathogenesis
AU - Jenner, Peter
AU - Morris, Huw R
AU - Robbins, Trevor W
AU - Goedert, Michel
AU - Hardy, John
AU - Ben-Shlomo, Yoav
AU - Bolam, Paul
AU - Burn, David
AU - Hindle, John V
AU - Brooks, David
PY - 2013
Y1 - 2013
N2 - The definition of Parkinson's disease (PD) is changing with the expansion of clinical phenomenology and improved understanding of environmental and genetic influences that impact on the pathogenesis of the disease at the cellular and molecular level. This had led to debate and discussion with as yet, no general acceptance of the direction that change should take either at the level of diagnosis or of what should and should not be sheltered under an umbrella of PD. This article is one contribution to this on-going discussion. There are two different themes running through the article--widening the definition of PD/LBD/synucleinopathies and the heterogeneity that exists within PD itself from a clinical, pathological and genetic perspective. The conclusion reached is that in the future, further diagnostic categories will need to be recognized. These are likely to include--Parkinson's syndrome, Parkinson's syndrome likely to be Lewy body PD, clinical PD (defined by QSBB criteria), Lewy body disease (PD, LBD, REM SBD) and synucleinopathies (including LBD, MSA).
AB - The definition of Parkinson's disease (PD) is changing with the expansion of clinical phenomenology and improved understanding of environmental and genetic influences that impact on the pathogenesis of the disease at the cellular and molecular level. This had led to debate and discussion with as yet, no general acceptance of the direction that change should take either at the level of diagnosis or of what should and should not be sheltered under an umbrella of PD. This article is one contribution to this on-going discussion. There are two different themes running through the article--widening the definition of PD/LBD/synucleinopathies and the heterogeneity that exists within PD itself from a clinical, pathological and genetic perspective. The conclusion reached is that in the future, further diagnostic categories will need to be recognized. These are likely to include--Parkinson's syndrome, Parkinson's syndrome likely to be Lewy body PD, clinical PD (defined by QSBB criteria), Lewy body disease (PD, LBD, REM SBD) and synucleinopathies (including LBD, MSA).
KW - Cognition Disorders
KW - Early Diagnosis
KW - Heterozygote
KW - Humans
KW - Lewy Body Disease
KW - Mutation
KW - Parkinson Disease
KW - Psychomotor Disorders
KW - Synucleins
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.3233/JPD-130175
DO - 10.3233/JPD-130175
M3 - Review article
C2 - 23938306
VL - 3
SP - 1
EP - 11
JO - Journal of Parkinson's disease
JF - Journal of Parkinson's disease
SN - 1877-7171
IS - 1
ER -